m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04131)
Name
Xentuzumab
Status
Phase 2
TTD Drug ID
D04DNB
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Insulin-like growth factor-I (IGF1)
Insulin-like growth factor-binding protein 3 (IGFBP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor-I (IGF1) is a therapeutic target for Xentuzumab. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of Xentuzumab through regulating the expression of Insulin-like growth factor-I (IGF1). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor-I (IGF1) is a therapeutic target for Xentuzumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Xentuzumab through regulating the expression of Insulin-like growth factor-I (IGF1). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor-I (IGF1) is a therapeutic target for Xentuzumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Xentuzumab through regulating the expression of Insulin-like growth factor-I (IGF1). [2], [3]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor-I (IGF1) is a therapeutic target for Xentuzumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Xentuzumab through regulating the expression of Insulin-like growth factor-I (IGF1). [2], [3]
Insulin-like growth factor-II (IGF2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor-II (IGF2) is a therapeutic target for Xentuzumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Xentuzumab through regulating the expression of Insulin-like growth factor-II (IGF2). [4], [5]
References
Ref 1 IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling. Mol Cancer Res. 2017 Jul;15(7):896-904. doi: 10.1158/1541-7786.MCR-16-0390. Epub 2017 Mar 22.
Ref 2 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
Ref 3 Cap-independent mRNA translation is upregulated in long-lived endocrine mutant mice. J Mol Endocrinol. 2019 Aug 1;63(2):123-138. doi: 10.1530/JME-19-0021.
Ref 4 The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018 Feb;52(2):621-629. doi: 10.3892/ijo.2017.4219. Epub 2017 Dec 7.
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)